Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA (vol 35, pg 160, 2019)

被引：0
|
作者：
McCafferty, Emma H. [1 ]
Lyseng-Williamson, Katherine Ann [1 ]
机构：
[1] Springer, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2019年 / 35卷 / 09期
关键词：
D O I：
10.1007/s40267-019-00645-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The original article has been corrected.
引用
收藏
页码：460 / 460
页数：1
相关论文
共 50 条
  • [41] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA
    Anthony Markham
    Zaina T. Al-Salama
    Drugs & Therapy Perspectives, 2022, 38 : 261 - 267
  • [42] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA
    Markham, Anthony
    Al-Salama, Zaina T.
    DRUGS & THERAPY PERSPECTIVES, 2022, 38 (06) : 261 - 267
  • [43] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study (vol 37, pg 2722, 2019)
    Hillmen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) : 1644 - 1644
  • [44] Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia ( vol 122 , 106946, 2022)
    Klink, Andrew J.
    Gajra, Ajeet
    Knoth, Russell L.
    Marshall, Landon
    Hou, Ying
    McBride, Ali
    Copher, Ronda
    LEUKEMIA RESEARCH, 2024, 136
  • [45] Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: Results from a bridging registrational study
    Wang, J.
    Jin, J.
    Yin, Q.
    Sun, M.
    Liang, Y.
    Chang, C.
    Zheng, J.
    Li, J.
    Ji, C.
    Zhang, J.
    Li, J.
    Gong, Y.
    Luo, S.
    Zhang, Y.
    Chen, R.
    Shen, Z.
    Yu, X.
    Liu, K.
    Yang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S773 - S773
  • [46] Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study
    Usuki, Kensuke
    Sakura, Toru
    Kobayashi, Yukio
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Morita, Satoshi
    Bahceci, Erkut
    Kaneko, Masahito
    Kusano, Mikiko
    Yamada, Shunsuke
    Takeshita, Shigeru
    Miyawaki, Shuichi
    Naoe, Tomoki
    CANCER SCIENCE, 2018, 109 (10): : 3235 - 3244
  • [47] Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (vol 39, pg 57, 2021)
    DiNardo, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) : 341 - 341
  • [48] A Single Center Analysis of Clofarabine Use Prior to Bone Marrow Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Scheckel, Caleb J.
    Betcher, Jeffrey Alan
    Sproat, Lisa
    Khera, Nandita
    Slack, James L.
    Leis, Jose F.
    Noel, Pierre
    Tibes, Raoul
    Mi, Lanyu
    Palmer, Jeanne
    BLOOD, 2017, 130
  • [49] Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia
    Qu, Wenqiang
    Lu, Jialing
    Ji, Yujie
    He, Zhewei
    Hou, Mengjia
    Li, Dongyang
    Yang, Yan
    Liu, Dan
    Chen, Suning
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (04) : 635 - 639
  • [50] Off-Label Use of Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia: A Single Institution Experience
    Gaut, Daria
    Burkenroad, Aaron
    Duong, Tuyen
    Feammelli, Jesse
    Sasine, Joshua
    Schiller, Gary J.
    BLOOD, 2019, 134
12345